AMITRIPTYLINE MARKET ANALYSIS

Amitriptyline Market, By Strength (10 mg tablets, 25 mg tablets, 50 mg tablets, 75 mg tablets, 100 mg tablets, 150 mg tablets), By Indication (Depression, Nocturnal Enuresis, Migraine, Chronic Neuropathic Pain, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Sep 2023
Code : CMI4226
Pages :180
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Global Amitriptyline Market: Key Developments

On March 30, 2023, AlgoTx, a France-based clinical stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had cleared the Investigational New Drug Application (IND) for its Phase 2 first-in-class candidate ATX01 (amitriptyline) in the treatment of erythromelalgia.
On March 30, 2023, AlgoTx, a France-based clinical stage biotechnology company, announced that the first patients have been randomized into the “ATX01 for the pain of ChemoTherapy” (ACT) study in Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Global Amitriptyline Market: Key Players

Major players operating in the global amitriptyline market include Accord Healthcare Inc., Viatris Inc., Sandoz Inc., Sun Pharmaceutical Industries Inc., Vintage Pharmaceuticals Inc., Zydus Pharmaceuticals USA Inc., Watson laboratories Inc., Torrent Pharmaceuticals Ltd., Dr Reddy's Laboratories Ltd., Unichem Laboratories Ltd., Apotex Inc., and Intas Pharmaceuticals Ltd.

Amitriptyline Market Report Snapshots